Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Alkermes (NASDAQ:ALKS) said its oral OX2R agonist ALKS 7290 showed dose-dependent clinical improvements and favorable safety in adults with ADHD, with Phase 2 now enrolling. The company also added Anne C. Whitaker to its board through 2027.
Alkermes announced positive topline results from a Phase 1b proof-of-concept study evaluating its investigational orexin 2 receptor agonist, ALKS 7290, in adults with attention-deficit hyperactivity disorder (ADHD). The drug demonstrated clinically meaningful improvements in ADHD symptoms.
Alkermes reported positive Phase 1b topline results for ALKS 7290 in adults with ADHD. The investigational orexin 2 receptor agonist showed clinically meaningful symptom improvement versus baseline, supporting further development in ADHD. Safety profile was generally tolerable in healthy volunteers and adult patients;
Alkermes said its Phase 1b proof-of-concept for ALKS 7290, an oral OX2R agonist, showed dose-dependent improvements on exploratory ADHD scales after 14 days and a favorable safety profile. A Phase 2 adult ADHD study is enrolling.
Alkermes said it has positive topline results from a Phase 1 proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor (OX2R) agonist, in adults with attention-deficit hyperactivity disorder (ADHD).